• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Reversing the effects of the new anti-clotting drugs
The oral anticoagulant warfarin (Coumadin) became available for prescription in 1954. This anti-clotting drug commanded national attention when President Dwight Eisenhower received the drug as part of his treatment following a heart attack. No other oral anticoagulant was successfully developed and marketed in the United States until 2010. Warfarin is a dangerous drug. Along with insulin, it is responsible for the most emergency hospitalizations due to adverse drug reactions. Whereas insulin causes low blood sugar, warfarin is notorious for the complication of major bleeding. Warfarin is plagued by hundreds of drug-drug an...
Source: New Harvard Health Information - December 9, 2015 Category: Consumer Health News Authors: Samuel Z. Goldhaber, MD Tags: Drugs and Supplements Health Heart Health Hypertension and Stroke anti-clotting coumadin deep-vein-thrombosis DVT Source Type: news

Apixaban vs Warfarin in Patients With Atrial FibrillationApixaban vs Warfarin in Patients With Atrial Fibrillation
Are the rates of stroke/systemic embolism and major bleeding lower among patients assigned to apixaban -- irrespective of prior vitamin K antagonist use? American Heart Journal
Source: Medscape Today Headlines - November 7, 2013 Category: Consumer Health News Tags: Cardiology Journal Article Source Type: news

AF Guideline Update Prefers NOACs to Warfarin in Most Cases AF Guideline Update Prefers NOACs to Warfarin in Most Cases
More nuanced use of stroke-risk scores, percutaneous LAA occlusion, insights into AF complicating ACS, and ascendant non-vitamin-K oral anticoagulants top an AHA/ACC/HRS update to 2014 AF guidelines.Medscape Medical News
Source: Medscape Medical News Headlines - January 31, 2019 Category: Consumer Health News Tags: Cardiology News Source Type: news